The Lynx Group
Cholangiocarcinoma News

Importance of PKN2 Signaling in the Development of Drug Resistance in Patients with CCA and FGFR2 Fusion

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Preclinical evidence presented at the AACR meeting implicates PKN2 signaling in resistance mechanisms in patients with FGFR2 fusion–positive intrahepatic CCA.

Chemotherapy, radiation, and surgery are all conventional antitumor therapies. After the identification of molecular aberrations as drivers for carcinogenesis, the introduction of therapies targeting specific tumor-promoting pathways has revolutionized the development of cancer therapeutics.

Significant progress has been made in cancer therapy, but oncologists often face the challenge of drug resistance, as many patients with cancer have resistance from the onset of treatment or after initial responses or several treatment cycles. This resistance results in acquired drug resistance and relapses, leading to increased mortality.

Resistance mechanisms in patients with FGFR2 fusion–positive intrahepatic CCA were investigated by Yeonjoo Hwang, BS, Staff Research Associate, University of California, San Francisco, and colleagues. Results were presented at this year’s annual meeting of the American Association for Cancer Research.

FGFR inhibition is associated with the rapid emergence of drug resistance. The mechanisms of FGFR resistance are diverse and include mutations that block drugs from binding to receptor sites. But it is becoming increasingly clear that individual tumors may achieve drug resistance via multiple routes simultaneously based on previous work.

Ms Hwang and colleagues used a phosphoproteomic (ie, a branch of proteomics that identifies, catalogs, and characterizes proteins that contain a phosphate group) analysis of the FGFR2-driven signaling response of a patient-derived FGFR2 fusion–positive intrahepatic CCA with cell line to the FGFR inhibitor TAS-120 (currently in phase 2 clinical trials, in development by Taiho Oncology). They identified a protein kinase, the PKN2, which significantly regulates the sensitivity to inhibition of FGFR fusion and FGFR signaling. PKN2 modulates signaling feedback through the AKT pathway after inhibition of FGFR fusion.

AKT is a key effector in PKN2-mediated FGFR resistance, and its pathway is important. When activated, AKT upregulates the NF-кB pathway, potentially leading to cell survival despite the inhibition of FGFR.

To validate that AKT is the pathway through which the PKN2 is regulating the NF-кB pathway, Ms Hwang and colleagues plan to continue this line of research, which will therefore contribute to drug resistance in patients with CCA and FGFR2 fusion.

Source: Hwang Y, et al. Cancer Res. 2020;80(16_suppl). Abstract 6572.

Related Items

Accelerated Approval Granted for Infigratinib for the Treatment of Metastatic Cholangiocarcinoma
Web Exclusives
Infigratinib has been approved to treat adults with previously treated locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Managing Cholangiocarcinoma in the Setting of COVID-19: Unique Challenges and Opportunities
By Ghassan K. Abou-Alfa, MD, MBA; Bruce Lin, MD; Farshid Dayyani, MD, PhD; Richard Kim, MD; Rachna T. Shroff, MD, MS; Melinda Bachini; Milind M. Javle, MD
December 2020, Special Issue: Managing CCA in the Setting of COVID-19
The first confirmed case in the United States of the 2019 novel coronavirus (COVID-19) was reported on January 21, 2020, and as of November 27, 2020, there were >63 million confirmed cases and >1.5 million deaths globally. Despite the global impact, certain populations have been identified as having a higher risk of developing severe COVID-19 infection, including patients with cancer. Various studies have shown that patients with cancer experience particularly poor outcomes after COVID-19 infection. As a result of the pandemic, care delivery has been disrupted to some degree based on the need for prioritization and limitations on resources. Therefore, healthcare providers and patients have been continually reassessing the balance between the benefits and risks of anticancer interventions in the context of the added risk of COVID-19 infection.
Cholangiocarcinoma Year in Review Introduction
2020 Year in Review: Cholangiocarcinoma
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!
Toripalimab, Lenvatinib, plus Chemotherapy a Promising Combination in Advanced Unresectable Intrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
The multidrug combination of toripalimab, lenvatinib plus chemotherapy with gemcitabine and oxaliplatin showed promising efficacy and tolerability in patients with intrahepatic CCA.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: